Key statistics
As of last trade Organon & Co (7XP:STU) traded at 16.30, -20.87% below its 52-week high of 20.60, set on Jul 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.41 |
---|---|
High | 16.63 |
Low | 16.23 |
Bid | 16.37 |
Offer | 16.65 |
Previous close | 16.61 |
Average volume | 283.33 |
---|---|
Shares outstanding | 257.47m |
Free float | 257.03m |
P/E (TTM) | 4.66 |
Market cap | 4.67bn USD |
EPS (TTM) | 3.89 USD |
Annual div (ADY) | 1.02 EUR |
---|---|
Annual div yield (ADY) | 6.23% |
Div ex-date | Aug 16 2024 |
Div pay-date | Sep 12 2024 |
Data delayed at least 15 minutes, as of Oct 07 2024.
More ▼
Press releases
- Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
- Organon Reports Results for the Second Quarter Ended June 30, 2024